Steps forward in Breast and Ovarian Drug Resistance
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 15 February 2025 | Viewed by 31
Special Issue Editors
Interests: cell
2. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
Interests: HER2; breast cancer; invasion; metastasis; drug screening; lysosome; transcription factor; signal transduction; autophagy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent breakthroughs in breast and ovarian cancers (BC, OC) highlight the growing need for molecular predictors paving the way for personalized care.
After the paradigm shift due to the advent of CDK 4/6 inhibitors and next-generation ER antagonists in ER+ BC, acquiring knowledge on acquired endocrine resistance is a major clinical challenge. The high prevalence of ESR1 gene mutations in anti-estrogen-treated metastatic disease underscores the “evolvability” of ER+ BC under the pressure of anti-oestrogen therapies. A better understanding of molecular processes underlying this evolution is needed. In the metastatic triple-negative BC (mTNBC) setting, preclinical research efforts on predictive biomarkers for Sacituzumab Govitecan efficacy in Trop-2-expressing mTNBC are growing; further insights into the underlying molecular hallmarks may help clarify multifaceted drug resistance.
Despite the latest advances in newly diagnosed OC, early relapse in patients due to chemoresistance poses a major clinical issue. Further investigation into putative biomarkers for drug resistance, including cancer stem cells, circulating tumor cells and miRNAs, is mandatory before their routine implementation.
This Special Issue focus on cellular and molecular hallmarks of endocrine resistance for ER+ MBC and drug resistance for ovarian cancer research. In this Special Issue, original research and review articles are welcome.
Dr. Simona Frezzini
Dr. Tuula Kallunki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- endocrine resistance
- ESR1 mutations
- Trop-2
- ovarian cancer
- drug resistance
- predictive biomarkers
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
